Nuevocor secures $24M for cardiac gene therapies
Nuevocor has completed a $24 million financing round to accelerate the preclinical development of its lead program, an adeno-associated virus-based gene therapy for patients with cardiomyopathy due to mutations in the lamin A/C (LMNA) gene. Read More
LIMS Wizards launches new SampleVision mobile app
LIMS Wizards recently announced the availability of SampleVision 2.0, a customer portal that allows sites to request analyses and retrieve test results. Read More
FibroGen, HiFiBiO partner on 3 therapies
FibroGen and HiFiBiO Therapeutics announced a partnership covering three HiFiBiO programs in immuno-oncology and autoimmune therapy. Read More
Eisai, BMS to develop antibody drug conjugate for solid tumors
Eisai and Bristol Myers Squibb (BMS) have entered a global strategic collaboration to develop and commercialize MORAb-202, an antibody drug conjugate. Read More
Vectron to buy protein production platform from T3S
Vectron Biosolutions announced it recently raised $2.7 million and will buy a bacterial secretion platform from Utah-based T3S Technologies. Read More
Solvias acquires Chemic Labs
Switzerland-based contract research organization and contract development and manufacturing organization Solvias announced it has inked a deal to buy Chemic Laboratories, a move it said will help it gain a stronger foothold in the U.S. Read More
Kite and Shoreline partner on allogeneic cell therapies
Biopharmaceutical company Kite announced a partnership with Shoreline Biosciences to develop novel cell therapies across a variety of cancer targets. Read More
Apollo Therapeutics nabs $145M to advance therapeutic programs
Apollo Therapeutics has raised $145 million in financing to support the advancement of the company's pipeline, including establishing a presence in Boston, MA. Read More
Dendreon to offer end-to-end cell therapy manufacturing
California-based Dendreon Pharmaceuticals announced that it will offer end-to-end manufacturing for complex cell therapies. Read More
Medidata offers trial decentralization platform
Medidata has launched an end-to-end unified platform for the decentralization of clinical trials. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter